> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Enzyvant Wins Priority Review Voucher
- URL: https://www.fdaweb.com/enzyvant-wins-priority-review-voucher/
- Published: 2021-10-28T12:00:00.000Z
- Updated: 2026-09-14T17:20:45.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150466

*Federal Register* notice: FDA has issued a priority review voucher to Enzyvant Therapeutics in response to its approval of a qualified rare pediatric disease product application. The agency determined that the company’s Rethymic (allogeneic processed thymus tissue-agdc), indicated for immune reconstitution in pediatric patients with congenital athymia, meets the criteria for a priority review voucher. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23336.pdf?ref=fdaweb.com).